• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by ADMA Biologics Inc

    8/11/25 6:41:13 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADMA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    ADMA BIOLOGICS INC

    (Name of Issuer)


    COMMON STOCK

    (Title of Class of Securities)


    000899104

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    000899104


    1Names of Reporting Persons

    STATE STREET CORPORATION
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MASSACHUSETTS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    11,187,440.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    12,078,505.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    12,078,505.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.1 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    ADMA BIOLOGICS INC
    (b)Address of issuer's principal executive offices:

    465 ROUTE 17 SOUTH , RAMSEY, NEW JERSEY, 7446
    Item 2. 
    (a)Name of person filing:

    STATE STREET CORPORATION;
    (b)Address or principal business office or, if none, residence:

    ONE CONGRESS STREET, SUITE 1, BOSTON MA 02114, UNITED STATES
    (c)Citizenship:

    MA
    (d)Title of class of securities:

    COMMON STOCK
    (e)CUSIP No.:

    000899104
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    12078505.00
    (b)Percent of class:

    5.1  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    11,187,440

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    12,078,505

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    NOT APPLICABLE
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    SSGA FUNDS MANAGEMENT, INC. (IA);STATE STREET GLOBAL ADVISORS EUROPE LIMITED (IA);STATE STREET GLOBAL ADVISORS LIMITED (IA);STATE STREET GLOBAL ADVISORS TRUST COMPANY (IA);STATE STREET GLOBAL ADVISORS, AUSTRALIA, LIMITED (IA);STATE STREET GLOBAL ADVISORS, LTD. (IA);
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    NOT APPLICABLE
    Item 9.Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.


    NOT APPLICABLE

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    STATE STREET CORPORATION
     
    Signature:ELIZABETH SCHAEFER
    Name/Title:SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER
    Date:08/08/2025
    Get the next $ADMA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADMA

    DatePrice TargetRatingAnalyst
    7/19/2023$5.00Strong Buy
    Raymond James
    10/13/2022$5.00Buy
    Mizuho
    11/11/2021$5.00Outperform → Strong Buy
    Raymond James
    11/9/2021$4.50Overweight
    Cantor Fitzgerald
    10/26/2021$6.00 → $5.00Outperform
    Raymond James
    8/12/2021$7.00 → $6.00Buy
    HC Wainwright & Co.
    7/6/2021$10.00 → $7.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ADMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative

    RAMSEY, N.J. and BOCA RATON, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced a capital return initiative target of approximately $200 million during 2026, including the execution of a $125 million accelerated share repurchase ("ASR") agreement with JPMorgan Chase Bank, National Association ("JPMorgan"). The initiative underscores the Company's strong financial position, durable free cash flow profile and confidence in its long-term growth trajectory. "We believe ADMA's common stock rep

    3/2/26 7:00:00 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth FY 2025 Adjusted Net Income(1) of $161 Million, Representing 35% Year-Over-Year Growth FY 2025 Adjusted EBITDA(2) of $231 Million, Representing 40% Year-Over-Year Growth Incoming CFO Appointment Expected to Further Enhance Financial Strategy, Working Capital Execution and Capital Allocation Discipline Advancing SG-001 Pipeline Program with Anticipated FDA Pre-IND Meeting in 2026; Potential Accelerated Path to Registrational Trial Ongoing Share Repurchases and Capital Structure to Increase Stockholder Value Reiterating Previo

    2/25/26 4:05:00 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

    RAMSEY, N.J. and BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that it will report fourth quarter and full year 2025 financial results on February 25, 2026, after the U.S. financial markets close. ADMA's management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call seamlessly, participants are required to register for the call here to receive the dial

    2/18/26 7:00:00 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMA
    SEC Filings

    View All

    $ADMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    ADMA Biologics Inc filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - ADMA BIOLOGICS, INC. (0001368514) (Filer)

    3/2/26 7:05:40 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by ADMA Biologics Inc

    10-K - ADMA BIOLOGICS, INC. (0001368514) (Filer)

    2/25/26 5:16:08 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ADMA Biologics Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - ADMA BIOLOGICS, INC. (0001368514) (Filer)

    2/25/26 4:11:12 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Grossman Adam S covered exercise/tax liability with 54,858 shares, decreasing direct ownership by 2% to 2,204,728 units (SEC Form 4)

    4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)

    3/2/26 9:00:14 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New insider Kohler Terry claimed ownership of 58,019 shares (SEC Form 3)

    3 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)

    2/26/26 9:00:15 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    COO and SVP, Compliance Kestenberg-Messina Kaitlin M. covered exercise/tax liability with 8,161 shares, decreasing direct ownership by 1% to 572,160 units (SEC Form 4)

    4 - ADMA BIOLOGICS, INC. (0001368514) (Issuer)

    2/23/26 9:00:19 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James resumed coverage on ADMA Biologics with a new price target

    Raymond James resumed coverage of ADMA Biologics with a rating of Strong Buy and set a new price target of $5.00

    7/19/23 9:02:26 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Mizuho initiated coverage on ADMA Biologics with a new price target

    Mizuho initiated coverage of ADMA Biologics with a rating of Buy and set a new price target of $5.00

    10/13/22 7:18:25 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ADMA Biologics upgraded by Raymond James with a new price target

    Raymond James upgraded ADMA Biologics from Outperform to Strong Buy and set a new price target of $5.00

    11/11/21 6:21:44 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMA
    Financials

    Live finance-specific insights

    View All

    ADMA Biologics to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

    RAMSEY, N.J. and BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that it will report fourth quarter and full year 2025 financial results on February 25, 2026, after the U.S. financial markets close. ADMA's management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call seamlessly, participants are required to register for the call here to receive the dial

    2/18/26 7:00:00 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business Update

    3Q 2025 Total Revenue of $134.2 Million, a 12% YoY Increase  3Q 2025 GAAP Net Income of $36.4 Million, a 1% YoY Increase 3Q 2025 Adjusted EBITDA(1) of $58.7 Million, a 29% YoY Increase 3Q 2025 Adjusted Net Income(2) of $38.9 Million, an 8% YoY Increase FDA Lot Release of First Yield-Enhanced Production Batches Positions ADMA for Margin Expansion Beginning in 4Q 2025 and Continuing Through 2026 Positive, Statistically Significant Real-World Health Outcomes Demonstrated for ASCENIV™ Record ASCENIV Demand and Anticipated 2026 Payer Coverage Expansion Support Sustained and Accelerating Revenue Growth Trajectory Advancing SG-001 Pipeline Program and CNPV Voucher Application Submitted; S

    11/5/25 4:05:00 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ADMA Biologics to Report Third Quarter 2025 Financial Results on November 5, 2025

    RAMSEY, N.J. and BOCA RATON, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced that it will report third quarter 2025 financial results on November 5, 2025, after the U.S. financial markets close. ADMA's management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and

    10/29/25 7:00:00 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMA
    Leadership Updates

    Live Leadership Updates

    View All

    ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth FY 2025 Adjusted Net Income(1) of $161 Million, Representing 35% Year-Over-Year Growth FY 2025 Adjusted EBITDA(2) of $231 Million, Representing 40% Year-Over-Year Growth Incoming CFO Appointment Expected to Further Enhance Financial Strategy, Working Capital Execution and Capital Allocation Discipline Advancing SG-001 Pipeline Program with Anticipated FDA Pre-IND Meeting in 2026; Potential Accelerated Path to Registrational Trial Ongoing Share Repurchases and Capital Structure to Increase Stockholder Value Reiterating Previo

    2/25/26 4:05:00 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ADMA Biologics Set to Join S&P SmallCap 600 Index

    RAMSEY, N.J. and BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced it will join the S&P SmallCap 600 index, effective prior to the open of trading on Monday, September 23, 2024. The S&P SmallCap 600 seeks to measure the small-cap segment of the U.S. equity market. "ADMA's inclusion in the S&P SmallCap 600 index is a significant milestone for our company," Adam Grossman, President and Chief Executive Officer of ADMA. "We expect this inclusion will increase our visibility within the investment communit

    9/17/24 7:00:00 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from

    9/6/24 6:43:00 PM ET
    $AAL
    $ADMA
    $ADNT
    Air Freight/Delivery Services
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ADMA Biologics Inc

    SC 13G/A - ADMA BIOLOGICS, INC. (0001368514) (Subject)

    11/12/24 1:34:17 PM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by ADMA Biologics Inc

    SC 13G - ADMA BIOLOGICS, INC. (0001368514) (Subject)

    11/8/24 9:21:37 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by ADMA Biologics Inc

    SC 13G - ADMA BIOLOGICS, INC. (0001368514) (Subject)

    11/4/24 11:00:41 AM ET
    $ADMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care